COX-2 Inhibitors, APC and Colon Cancer Prevention
COX-2 抑制剂、APC 和结肠癌预防
基本信息
- 批准号:7568910
- 负责人:
- 金额:$ 23.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:Adenomatous Polyposis ColiAffectAnabolismCCND1 geneCell NucleusCessation of lifeClinical DataClinical ResearchClinical TrialsColon CarcinomaColorectalColorectal CancerColorectal NeoplasmsColorectal PolypCoxibsDataDeveloped CountriesDinoprostoneDiseaseEGF geneEicosanoidsEngineeringEpidemiologic StudiesEpidemiologyEpidermal Growth Factor ReceptorEventFailureFeedbackGene TargetingGenesGenetic TranscriptionGrowth FactorHealthHigh PrevalenceIn VitroIncidenceIntestinal NeoplasmsKnowledgeLaboratory StudyLinkMediatingMessenger RNAMolecular TargetMusMutationPTEN genePathogenesisPathway interactionsPatientsPlayPost-Transcriptional RegulationPreventionProstaglandin H2ProstaglandinsRiskRofecoxibRoleSignal InductionSignal TransductionTimeTranslationsTumor Suppressor Genesbcl-1 Genesbeta cateninc-myc Genescancer preventioncarcinogenesiscelecoxibcell growthclinically relevantcyclooxygenase 2functional lossin vivomortalitymouse PGE synthase 1mutantoverexpressionpolyposispre-clinicalpreventprostaglandin E synthaseresearch studysuccesstherapeutic targettumor progression
项目摘要
DESCRIPTION (provided by applicant): Mutations in the APC tumor suppressor gene cause FAP and are detected in approximately 80% of sporadic colorectal cancers. A loss of functional APC results in activation of TCF/Beta-catenin-mediated transcription. Activation of this pathway alters the expression of numerous genes, e.g., COX-2, that have been implicated in the pathogenesis of colorectal cancer. Preclinical and clinical studies have highlighted the potential importance of COX-2 as a therapeutic target for preventing and possibly treating colorectal cancer. The long-term objective of this application is to better understand the mechanistic link between APC, COX-2 and colorectal carcinogenesis as well as the mechanism(s) of action of selective COX-2 inhibitors. We have shown that activation of Beta-catenin signaling stimulates prostanoid biosynthesis by inducing COX-2 and mPGES-1. Notably, deregulated TCF/Beta-catenin signaling stimulated the transcription of both genes, stabilized COX-2 mRNA while blocking its translation. Activation of EGFR/Ras signaling, a common event in colorectal neoplasia, relieved this translational block. In one aim, we will define the mechanisms underlying these effects. A second aim will be to characterize the effects of COX-2-derived products on downstream pathways that have been implicated in carcinogenesis. This aim is supported by preliminary evidence that PGE2 and TXA2 activate TCF/Beta-catenin-mediated transcription and EGFR signaling suggesting cross-talk between these pathways. Additionally, PGE2 and TXA2 altered the post-transcriptional control of TCF/Beta-catenin target genes suggesting that eicosanoids affect cell growth by multiple mechanisms. Finally, we have shown that celecoxib "normalizes" deregulated TCF/Beta-catenin-mediated transcription by a COX-2- independent mechanism. Hence, a third aim will be to perform additional in vitro and in vivo studies to further evaluate these effects. These studies will enhance our understanding of the mechanistic link between COX-2 and colorectal cancer and potentially assist us in optimizing the use of selective COX-2 inhibitors as therapy.
描述(由申请人提供):APC 肿瘤抑制基因的突变会导致 FAP,并在大约 80% 的散发性结直肠癌中检测到。功能性 APC 的丧失会导致 TCF/β-连环蛋白介导的转录激活。该通路的激活会改变许多基因的表达,例如 COX-2,这些基因与结直肠癌的发病机制有关。临床前和临床研究强调了 COX-2 作为预防和可能治疗结直肠癌的治疗靶点的潜在重要性。本申请的长期目标是更好地了解 APC、COX-2 与结直肠癌发生之间的机制联系以及选择性 COX-2 抑制剂的作用机制。我们已经证明,β-连环蛋白信号传导的激活通过诱导 COX-2 和 mPGES-1 来刺激前列腺素生物合成。值得注意的是,失调的 TCF/β-连环蛋白信号传导刺激了这两个基因的转录,稳定了 COX-2 mRNA,同时阻断了其翻译。 EGFR/Ras 信号传导的激活(结直肠肿瘤中的常见事件)缓解了这种翻译障碍。我们的一个目标是定义这些影响背后的机制。第二个目标是表征 COX-2 衍生产物对与致癌有关的下游途径的影响。这一目标得到了初步证据的支持,即 PGE2 和 TXA2 激活 TCF/β-连环蛋白介导的转录和 EGFR 信号传导,表明这些途径之间存在串扰。此外,PGE2 和 TXA2 改变了 TCF/β-catenin 靶基因的转录后控制,表明类二十烷酸通过多种机制影响细胞生长。最后,我们发现塞来昔布通过 COX-2 独立机制使 TCF/β-连环蛋白介导的转录失调“正常化”。因此,第三个目标是进行额外的体外和体内研究以进一步评估这些影响。这些研究将增强我们对 COX-2 与结直肠癌之间机制联系的理解,并可能帮助我们优化选择性 COX-2 抑制剂的治疗用途。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes.
胆汁酸抑制结肠细胞中 NAD 依赖性 15-羟基前列腺素脱氢酶转录。
- DOI:10.1152/ajpgi.00133.2009
- 发表时间:2009
- 期刊:
- 影响因子:0
- 作者:Miyaki,Akira;Yang,Peiying;Tai,Hsin-Hsiung;Subbaramaiah,Kotha;Dannenberg,AndrewJ
- 通讯作者:Dannenberg,AndrewJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KOTHA SUBBARAMAIAH其他文献
KOTHA SUBBARAMAIAH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KOTHA SUBBARAMAIAH', 18)}}的其他基金
COX-2 Inhibitors, APC and Colon Cancer Prevention
COX-2 抑制剂、APC 和结肠癌预防
- 批准号:
7216280 - 财政年份:2005
- 资助金额:
$ 23.7万 - 项目类别:
COX-2 Inhibitors, APC and Colon Cancer Prevention
COX-2 抑制剂、APC 和结肠癌预防
- 批准号:
6848984 - 财政年份:2005
- 资助金额:
$ 23.7万 - 项目类别:
COX-2 Inhibitors, APC and Colon Cancer Prevention
COX-2 抑制剂、APC 和结肠癌预防
- 批准号:
7364217 - 财政年份:2005
- 资助金额:
$ 23.7万 - 项目类别:
COX-2 Inhibitors, APC and Colon Cancer Prevention
COX-2 抑制剂、APC 和结肠癌预防
- 批准号:
7035938 - 财政年份:2005
- 资助金额:
$ 23.7万 - 项目类别:
相似国自然基金
METTL3通过m6A甲基化修饰NADK2调节脯氨酸代谢和胶原合成影响皮肤光老化的机制研究
- 批准号:82360625
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
多组学研究STAT3调控CKMT2和CD36-FABP4影响脂肪细胞参与乳腺癌细胞磷酸肌酸合成的耐药代谢重编程
- 批准号:82360604
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
结核分枝杆菌通过甲硫氨酸合成酶影响四氢叶酸代谢介导对氨基水杨酸耐药的分子机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
内源性应激状态、刻板行为及交互效应对奶牛机体代谢和乳合成的影响及其关联性研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
须糖多孢菌EⅡGlc与pyk基因修饰对葡萄糖代谢的协同作用及其对丁烯基多杀菌素生物合成的影响
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Novel resveratrol analogs and colorectal cancer treatment
新型白藜芦醇类似物和结直肠癌治疗
- 批准号:
8715739 - 财政年份:2013
- 资助金额:
$ 23.7万 - 项目类别:
Novel resveratrol analogs and colorectal cancer treatment
新型白藜芦醇类似物和结直肠癌治疗
- 批准号:
8847232 - 财政年份:2013
- 资助金额:
$ 23.7万 - 项目类别:
Novel resveratrol analogs and colorectal cancer treatment
新型白藜芦醇类似物和结直肠癌治疗
- 批准号:
8576714 - 财政年份:2013
- 资助金额:
$ 23.7万 - 项目类别:
Prevention of Colon Cancer by Epigallocatechin Gallate and Atorvastatin
表没食子儿茶素没食子酸酯和阿托伐他汀预防结肠癌
- 批准号:
7845194 - 财政年份:2009
- 资助金额:
$ 23.7万 - 项目类别:
Prevention of Colon Cancer by Epigallocatechin Gallate and Atorvastatin
表没食子儿茶素没食子酸酯和阿托伐他汀预防结肠癌
- 批准号:
8107848 - 财政年份:2008
- 资助金额:
$ 23.7万 - 项目类别: